Patents by Inventor Kenneth Allen Newlander

Kenneth Allen Newlander has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • TRIAZOLE-SUBSTITUTED IMIDAZO[1,2-A]PYRIMIDINES AS CGAS INHIBITORS
    Publication number: 20250092053
    Abstract: The present invention relates to compounds of Formula (I), compositions containing them, and to their use in the treatment of various disorders, in particular autoimmune, autoinflammatory or immune-mediated conditions, such as systemic lupus erythematosus (SLE), cutaneous lupus erythematosus (CLE) and lupus nephritis.
    Type: Application
    Filed: December 3, 2024
    Publication date: March 20, 2025
    Applicant: GlaxoSmithKline Intellectual Property Development Limited
    Inventors: Adam K. CHARNLEY, Janos Botyanszki, Xiaoyang Dong, Philip Gareth Humphreys, Bryan Wayne King, Kimberly Katherine Marcus, Joseph Pero, Alexander Joseph Reif, Daohua Zhang, Attiq Rahman, Kenneth Allen Newlander, Kenneth Wiggall, Joshi Ramanjulu
  • Triazole-substituted imidazo[1,2-a]pyrimidines as cGAS inhibitors
    Patent number: 12247033
    Abstract: The present invention relates to compounds of Formula (I), compositions containing them, and to their use in the treatment of various disorders, in particular autoimmune, autoinflammatory or immune-mediated conditions, such as systemic lupus erythematosus (SLE), cutaneous lupus erythematosus (CLE) and lupus nephritis.
    Type: Grant
    Filed: February 26, 2024
    Date of Patent: March 11, 2025
    Assignee: GlaxoSmithKline Intellectual Property Development Limited
    Inventors: Adam K. Charnley, Janos Botyanszki, Xiaoyang Dong, Philip Gareth Humphreys, Bryan Wayne King, Kimberly Katherine Marcus, Joseph Pero, Alexander Joseph Reif, Daohua Zhang, Attiq Rahman, Kenneth Allen Newlander, Kenneth Wiggall, Joshi Ramanjulu
  • Enhancer of zeste homolog 2 inhibitors
    Patent number: 9790212
    Abstract: This invention relates to novel compounds according to Formula (III)(a) which are inhibitors of Enhancer of Zeste Homolog 2 (EZH2), and to pharmaceutical compositions containing them.
    Type: Grant
    Filed: October 13, 2016
    Date of Patent: October 17, 2017
    Assignee: GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED
    Inventors: Charles William Blackledge, Jr., Joelle Lorraine Burgess, Neil W. Johnson, Jiri Kasparec, Steven David Knight, Louis V. LaFrance, III, Juan I. Luengo, William Henry Miller, Kenneth Allen Newlander, Stuart Paul Romeril, Mark Schulz, Dai-Shi Su, Xinrong Tian
  • Enhancer of zeste homolog 2 inhibitors
    Patent number: 9505745
    Abstract: This invention relates to novel compounds according to Formula (I) which are inhibitors of Enhancer of Zeste Homolog 2 (EZH2), to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy for the treatment of cancers.
    Type: Grant
    Filed: April 25, 2014
    Date of Patent: November 29, 2016
    Assignee: GlaxoSmithKline Intellectual Property (No. 2) Limited
    Inventors: Charles William Blackledge, Jr., Joelle Lorraine Burgess, Neil W. Johnson, Jiri Kasparec, Steven David Knight, Louis V. LaFrance, III, Juan I. Luengo, William Henry Miller, Kenneth Allen Newlander, Stuart Paul Romeril, Mark Schulz, Dai-Shi Su, Xinrong Tian
  • Indoles
    Patent number: 9402836
    Abstract: Herein are disclosed indoles of formula (I) where the various groups are defined herein, and which are useful for treating cancer.
    Type: Grant
    Filed: July 9, 2015
    Date of Patent: August 2, 2016
    Assignee: GlaxoSmithKline LLC
    Inventors: James Brackley, III, Joelle Lorraine Burgess, Seth Wilson Grant, Neil W. Johnson, Steven David Knight, Louis Vincent LaFrance, III, William Henry Miller, Kenneth Allen Newlander, Stuart Paul Romeril, Meagan B. Rouse, Xinrong Tian, Sharad Kumar Verma
  • Enhancer of Zeste Homolog 2 inhibitors
    Patent number: 9382234
    Abstract: This invention relates to novel compounds according to Formula (I) which are inhibitors of Enhancer of Zeste Homolog 2 (EZH2), to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy for the treatment of cancers.
    Type: Grant
    Filed: December 12, 2013
    Date of Patent: July 5, 2016
    Assignee: GlaxoSmithKline LLC
    Inventors: Steven David Knight, William Henry Miller, Kenneth Allen Newlander, Carla A. Donatelli
  • INDOLES
    Publication number: 20150313887
    Abstract: Herein are disclosed indoles of formula (I) where the various groups are defined herein, and which are useful for treating cancer.
    Type: Application
    Filed: July 9, 2015
    Publication date: November 5, 2015
    Inventors: James BRACKLEY, III, Joelle Lorraine Burgess, Seth Wilson Grant, Neil W. Johnson, Steven David Knight, Louis Vincent LaFrance, III, William Henry Miller, Kenneth Allen Newlander, Stuart Paul Romeril, Meagan B. Rouse, Xinrong Tian, Sharad Kumar Verma
  • Azaindazoles
    Patent number: 9073924
    Abstract: Herein are disclosed azaindazoles of formula (I) where the various groups are defined herein, and which are useful for treating cancer.
    Type: Grant
    Filed: September 12, 2012
    Date of Patent: July 7, 2015
    Assignee: GlaxoSmithKline LLC
    Inventors: Joelle Lorraine Burgess, Neil W. Johnson, Steven David Knight, Louis Vincent LaFrance, III, William Henry Miller, Kenneth Allen Newlander, Stuart Paul Romeril, Meagan B. Rouse, Dominic Suarez, Xinrong Tian, Sharad Kumar Verma
  • ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS
    Publication number: 20150126522
    Abstract: This invention relates to novel substituted benzamides according to Formula (I) which are inhibitors of Enhancer of Zeste Homolog 2 (EZH2), to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy for the treatment of cancers.
    Type: Application
    Filed: May 15, 2013
    Publication date: May 7, 2015
    Applicant: GlaxoSmithKline LLC
    Inventors: Joelle Lorraine Burgess, Celine Duquenne, Steven David Knight, William Henry Miller, Kenneth Allen Newlander, Sharad Kumar Verma
  • AZAINDAZOLES
    Publication number: 20140343056
    Abstract: Herein are disclosed azaindazoles of formula (I) where the various groups are defined herein, and which are useful for treating cancer.
    Type: Application
    Filed: September 12, 2012
    Publication date: November 20, 2014
    Applicant: GlaxoSmithKline LLC
    Inventors: Joelle Lorraine Burgess, Neil W. Johnson, Steven David Knight, Louis Vincent LaFrance, III, William Henry Miller, Kenneth Allen Newlander, Stuart Paul Romeril, Meagan B. Rouse, Dominic Suarez, Xinrong Tian, Sharad Kumar Verma
  • QUINOLINE DERIVATIVES AS PI3 KINASE INHIBITORS
    Publication number: 20140296224
    Abstract: Invented is a method of inhibiting the activity/function of PI3 kinases using quinoline derivatives. Also invented is a method of treating one or more disease states selected from: autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, allergy, asthma, pancreatitis, multiorgan failure, kidney diseases, platelet aggregation, cancer, sperm motility, transplantation rejection, graft rejection and lung injuries by the administration of quinoline derivatives.
    Type: Application
    Filed: June 17, 2014
    Publication date: October 2, 2014
    Inventors: Nicholas D. ADAMS, Joelle Lorraine Burgess, Michael Gerard Darcy, Carla A. Donatelli, Steven David Knight, Kenneth Allen Newlander, Lance Ridgers, Martha A. Sarpong, Stanley J. Schmidt
  • Indoles
    Patent number: 8765792
    Abstract: Herein are disclosed indoles of formula (I) where the various groups are defined herein, and which are useful for treating cancer.
    Type: Grant
    Filed: November 30, 2011
    Date of Patent: July 1, 2014
    Assignee: GlaxoSmithKline LLC
    Inventors: Steven David Knight, William Henry Miller, Kenneth Allen Newlander, Sharad Kumar Verma
  • INDOLES
    Publication number: 20130245016
    Abstract: Herein are disclosed indoles of formula (I) where the various groups are defined herein, and which are useful for treating cancer.
    Type: Application
    Filed: November 30, 2011
    Publication date: September 19, 2013
    Inventors: Steven David Knight, William Henry Miller, Kenneth Allen Newlander, Sharad Kumar Verma
  • Quinoline derivatives as P13 kinase inhibitors
    Patent number: 8404837
    Abstract: Invented is a method of inhibiting the activity/function of PI3 kinases using quinoline derivatives. Also invented is a method of treating one or more disease states selected from: autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, allergy, asthma, pancreatitis, multiorgan failure, kidney diseases, platelet aggregation, cancer, sperm motility, transplantation rejection, graft rejection and lung injuries by the administration of quinoline derivatives.
    Type: Grant
    Filed: May 16, 2008
    Date of Patent: March 26, 2013
    Assignee: GlaxoSmithKline LLC
    Inventors: Nicholas D. Adams, Joelle Lorraine Burgess, Michael Gerard Darcy, Carla A. Donatelli, Steven David Knight, Kenneth Allen Newlander, Lance Ridgers, Martha A. Sarpong, Stanley J. Schmidt
  • QUINOLINE DERIVATIVES AS PI3 KINASE INHIBITORS
    Publication number: 20120165321
    Abstract: Invented is a method of inhibiting the activity/function of PI3 kinases using quinoline derivatives. Also invented is a method of treating one or more disease states selected from: autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, allergy, asthma, pancreatitis, multiorgan failure, kidney diseases, platelet aggregation, cancer, sperm motility, transplantation rejection, graft rejection and lung injuries by the administration of quinoline derivatives.
    Type: Application
    Filed: March 5, 2012
    Publication date: June 28, 2012
    Inventors: Nicholas D. Adams, Joelle Lorraine Burgess, Michael Gerrard Darcy, Carla A. Donatelli, Steven David Knight, Kenneth Allen Newlander, Lance Ridgers, Martha A. Sarpong, Stanley J. Schmidt
  • PYRIDOSULFONAMIDE DERIVATIVES AS P13 KINASE INHIBITORS
    Publication number: 20100311736
    Abstract: Invented is a method of inhibiting the activity/function of PI3 kinases using pyridosulfonamide derivatives. Also invented is a method of treating one or more disease states selected from: autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, allergy, asthma, pancreatitis, multiorgan failure, kidney diseases, platelet aggregation, cancer, sperm motility, transplantation rejection, graft rejection and lung injuries by the administration of pyridosulfonamide derivatives.
    Type: Application
    Filed: October 22, 2008
    Publication date: December 9, 2010
    Inventors: Nicholas D. Adams, Michael Gerard Darcy, Neil W. Johnson, Jiri Kasparec, Steven David Knight, Kenneth Allen Newlander, Xin Peng, Lance H. Ridgers
  • PYRIDOPYRIMIDINE DERIVATIVES AS P13 KINASE INHIBITORS
    Publication number: 20100204222
    Abstract: Invented is a method of inhibiting the activity/function of PI3 kinases using pyridopyrimidine derivatives. Also invented is a method of treating one or more disease states selected from: autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, allergy, asthma, pancreatitis, multiorgan failure, kidney diseases, platelet aggregation, cancer, sperm motility, transplantation rejection, graft rejection and lung injuries by the administration of pyridopyrimidine derivatives.
    Type: Application
    Filed: September 17, 2008
    Publication date: August 12, 2010
    Inventors: Kenneth Allen Newlander, Cynthia A. Parrish
  • QUINAZOLINE DERIVATIVES AS P13 KINASE INHIBITORS
    Publication number: 20100179144
    Abstract: Invented is a method of inhibiting the activity/function of PI3 kinases using quinazoline derivatives. Also invented is a method of treating one or more disease states selected from: autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, allergy, asthma, pancreatitis, multiorgan failure, kidney diseases, platelet aggregation, cancer, sperm motility, transplantation rejection, graft rejection and lung injuries by the administration of quinazoline derivatives.
    Type: Application
    Filed: June 12, 2008
    Publication date: July 15, 2010
    Inventors: Nicholas D. Adams, Joelle Lorraine Burgess, Michael Gerard Darcy, Steven David Knight, Kenneth Allen Newlander, Lance H. Ridgers, Stanley J. Schmidt
  • Azaindole inhibitors of Aurora kinases
    Patent number: 7605266
    Abstract: The present invention relates to a compound represented by Formula (I): and pharmaceutically acceptable salts. Compounds of the present invention inhibit Aurora kinase, making them especially suitable for the treatment of a number of diseases, including solid tumor cancers and hematological cancers.
    Type: Grant
    Filed: August 4, 2008
    Date of Patent: October 20, 2009
    Assignee: SmithKline Beecham
    Inventors: Dashyant Dhanak, Kenneth Allen Newlander
  • Azaindole inhibitors of aurora kinases
    Patent number: 7495102
    Abstract: The present invention relates to a compound represented by Formula (I): and pharmaceutically acceptable salts. Compounds of the present invention inhibit Aurora kinase, making them especially suitable for the treatment of a number of diseases, including solid tumor cancers and hematological cancers.
    Type: Grant
    Filed: September 14, 2007
    Date of Patent: February 24, 2009
    Assignee: SmithKline Beecham Corporation
    Inventors: Martha A. Sarpong, Nicholas D. Adams, Jeffrey Michael Axten, Amita M. Chaudhari, Dashyant Dhanak, Toshihiro Hamajima, Kenneth Allen Newlander, Cynthia A. Parrish, Jerry Leroy Adams, Domingos J. Silva, Jun Tang